SoftBank Backs Dog DNA Startup Embark at $700 Million Valuation
- Firm aims to increase dog lifespans by three years this decade
- CEO says its database will top 1 million dogs in coming months
Photographer: Matt Cardy/Getty Images
This article is for subscribers only.
Softbank Group Corp.’s Vision Fund 2 led a $75 million funding round for Embark Veterinary Inc., a genetics startup that seeks to increase dog lifespans.
The transaction values the Boston-based company at $700 million, Embark Chief Executive Officer Ryan Boyko said in an interview.